Sun Pharma Advanced Research Company Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 1,310.9 million compared to INR 621.5 million a year ago. Revenue was INR 1,311.2 million compared to INR 624.9 million a year ago. Net income was INR 101.5 million compared to net loss of INR 158.4 million a year ago. Basic earnings per share from continuing operations was INR 0.37 compared to basic loss per share from continuing operations of INR 0.6 a year ago. Diluted earnings per share from continuing operations was INR 0.35 compared to diluted loss per share from continuing operations of INR 0.6 a year ago.
For the nine months, sales was INR 1,910.9 million compared to INR 1,120.1 million a year ago. Revenue was INR 1,912.4 million compared to INR 1,186.3 million a year ago. Net loss was INR 1,405.9 million compared to INR 1,323.5 million a year ago. Basic loss per share from continuing operations was INR 5.16 compared to INR 5.05 a year ago. Diluted loss per share from continuing operations was INR 5.16 compared to INR 5.05 a year ago.